+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Clinical study of paclitaxel plus cisplatin in the treatment of recurrent cervical cancer

Clinical study of paclitaxel plus cisplatin in the treatment of recurrent cervical cancer

Chinese-German Journal of Clinical Oncology 6(3): P282-P284

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 063549294

Download citation: RISBibTeXText

DOI: 10.1007/s10330-007-0007-6

Related references

A phase III trial of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in stage IVB, persistent or recurrent cervical cancer: Gynecologic Cancer Study Group/Japan Clinical Oncology Group Study (JCOG0505). Japanese Journal of Clinical Oncology 40(1): 90-93, 2010

Prognostic factors from a randomized phase III trial of paclitaxel and carboplatin versus paclitaxel and cisplatin in metastatic or recurrent cervical cancer: Japan Clinical Oncology Group (JCOG) trial: JCOG0505-S1. Cancer ChemoTherapy and Pharmacology 78(4): 785-790, 2016

A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer. Gynecologic Oncology 105(2): 299-303, 2007

Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Cisplatin in Metastatic or Recurrent Cervical Cancer: The Open-Label Randomized Phase III Trial JCOG0505. Journal of Clinical Oncology 33(19): 2129-2135, 2015

A phase II trial with cisplatin-paclitaxel cytotoxic treatment and concurrent external and endocavitary radiation therapy in locally advanced or recurrent cervical cancer. Oncology 70(1): 19-24, 2006

Phase II feasibility study of sequential couplets of Cisplatin/Topotecan followed by paclitaxel/cisplatin as primary treatment for advanced epithelial ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group Study. Journal of Clinical Oncology 18(24): 4038-4044, 2000

Clinical phase II study of paclitaxel followed by cisplatin in patients with recurrent head and neck cancer. Proceedings of the American Association for Cancer Research Annual Meeting 37(0): 168, 1996

Systematic Review and Network Meta-Analysis of Bevacizumab Plus First-Line Topotecan-Paclitaxel or Cisplatin-Paclitaxel Versus Non-Bevacizumab-Containing Therapies in Persistent, Recurrent, or Metastatic Cervical Cancer. International Journal of Gynecological Cancer 27(6): 1237-1246, 2017

A phase II study of paclitaxel and doxorubicin as second-line treatment in recurrent ovarian cancer after cisplatin failure. Gynecologic Oncology 68(1): 123, 1998

Paclitaxel, Ifosfamide and Cisplatin chemotherapy for recurrent or advanced squamous cell cervical cancer. European Journal of Cancer 35(SUPPL 4): S231, Sept, 1999

Paclitaxel, ifosfamide and cisplatin (TIP) chemotherapy for recurrent or persistent squamous-cell cervical cancer. Annals of Oncology 10(10): 1171-1174, 1999

The efficacy of paclitaxel and cisplatin combination chemotherapy for the treatment of metastatic or recurrent gastric cancer: a multicenter phase II study. Korean Journal of Internal Medicine 20(2): 135-140, 2005

A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer. Gynecologic Oncology 133(1): 117-123, 2014

A pilot feasibility study for cisplatin plus S-1 for the treatment for advanced or recurrent cervical cancer. Cancer ChemoTherapy and Pharmacology 71(5): 1369-1374, 2013

Quality of life (QOL) outcomes from a randomized trial of cisplatin versus cisplatin plus paclitaxel in advanced cervical cancer: a Gynecologic Oncology Group study. Gynecologic Oncology 101(2): 296-304, 2005